Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) will hold a conference call at 8:00 a.m. Eastern Time today to discuss results of their Phase 2 ACROBAT Edge and ACROBAT Evolve studies of paltusotine (formerly CRN00808), the company's lead candidate for the treatment of acromegaly.

Company Conference Call: Review of Phase 2 Paltusotine Results

Day /Time:October 26 at 8:00am ET

Dial in: 877-407-0789 (domestic) or 201-689-8562 (international)

Conference ID: 13712345

Click to join live webcast

Please note, an archive of this event will be available approximately 2 hours following the conclusion of the live call.

Attachments

  • Original document
  • Permalink

Disclaimer

Crinetics Pharmaceuticals Inc. published this content on 26 October 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 October 2020 04:29:05 UTC